The goal of the current study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing and vestibular function. CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1).
Estimated Enrollment: 45
Study Start Date: June 2014
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Hearing Loss
To evaluate CGF166 delivered through IL-infusion to improve hearing and vestibular function.